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Introduction {#sec1}
============

Biogenesis of eukaryotic secretory or transmembrane proteins often occurs at the surface of the endoplasmic reticulum through the process of co-translational translocation. Here proteins targeted to the membrane by a signal sequence are translocated during translation through a membrane-spanning protein conduit formed by the Sec61αβγ complex. An analogous system, SecYEG, is found in the plasma membrane of bacteria, where it also mediates protein secretion. The structure of the heterotrimeric Sec complex is conserved throughout evolution and contains the core channel-forming subunit Sec61α/SecY together with the smaller subunits Sec61β/SecG and Sec61γ/SecE ([@bib63]; [@bib68]). The translocon forms a gated channel that maintains membrane integrity while selectively opening to allow passage of the unfolded polypeptide chain. In addition, the translocon must open laterally to allow the transmembrane helices of membrane proteins to pass into the membrane environment as they are translated.

Structural studies of the translocon have provided snapshots of how this dynamic complex operates. Sec61α/SecY is formed from 10 transmembrane helices that are arranged in a "clamshell" architecture ([@bib63]). In the resting state, this forms a transmembrane channel, which is occluded by a central constriction of hydrophobic residues, known as the pore ring, and a short plug helix, which blocks the lumenal exit. A second potential opening, the lateral gate, lies at the interface between helices H2/H3 and H7/H8. This gate is stabilized by a polar cluster and is proposed to open to provide a route for translocating transmembrane helices to pass into the membrane ([@bib63]). During protein translocation, the plug helix is displaced to open the channel, whereas the dynamic opening and closing of the lateral gate is thought to allow regions of the elongating polypeptide to partition into the endoplasmic reticulum lumen or the membrane environment, depending on their hydrophobicity.

More recently, cryoelectron microscopy studies have allowed visualization of ribosome-translocon complexes in different stages of translocation. These show that ribosome binding primes the translocon, loosening the lateral gate and breaking the polar cluster ([@bib68]). During co-translational translocation, the N-terminal signal peptide interacts with a hydrophobic patch of residues near the lateral gate, occupying the position previously taken by helix H2 of Sec61α ([@bib66]). In this state, the plug helix is displaced, opening the channel for translocation. The translocon can also operate post-translationally, with the allosteric activators Sec62 and Sec63 stabilizing an activated conformation of Sec61α in which the cytoplasmic side of the lateral gate is open ([@bib26]; [@bib71]) but the plug helix remains in place ([@bib71]). This prepares the translocon to bind and be gated by weak signal peptides.

These studies reveal that the translocon is dynamic, with structural transitions modulated by associations with the signal peptide ([@bib19]) or allosteric activators ([@bib26]; [@bib71]). Open states are stabilized by binding partners that hold helices H2 and H3 in a conformation in which the lateral gate is open and the plug helix is displaced ([@bib15]; [@bib35]; [@bib51]; [@bib67]). There are also a number of inhibitors that act on Sec61α but no detailed molecular insight into how they modulate the structure or conformational dynamics of the translocon.

Two studies showed that selective inhibitors of protein secretion can block co-translational translocation by acting directly on Sec61 ([@bib4]; [@bib13]). Inhibitors of Sec61-dependent translocation that act in this way include mycolactone, apratoxin A, cotransin, and ipomoeassin F ([@bib9]; [@bib20]; [@bib21]; [@bib32]; [@bib40]; [@bib48]; [@bib75]). These molecules have diverse structures but compete when binding to Sec61α, suggesting that they bind to overlapping sites ([@bib2]; [@bib48]; [@bib75]). Indeed, mutations of Sec61α that cause resistance to one inhibitor often also cause resistance to the others, suggesting a shared mode of action. Despite this, different inhibitors show variable specificity for translocons from different species and block translocation of different classes of substrates, raising the possibility of developing therapeutically useful selective translocon modulators. Of the current inhibitors, mycolactone ([Figure 1](#fig1){ref-type="fig"}A) is the most potent ([@bib20]). This diffusible lipid-like exotoxin is synthesized by the Buruli ulcer pathogen *Mycobacterium ulcerans* ([@bib10]; [@bib72]) and forms a stable complex with Sec61α ([@bib2]). It prevents co-translational translocation of secretory proteins, including inflammatory mediators and cytokines, at nanomolar concentrations ([@bib2]; [@bib20]; [@bib41]) and blocks Sec61-dependent insertion of many transmembrane proteins ([@bib2]; [@bib42]). Mycolactone inhibits translocation at a stage after ribosome engagement with the translocon and affects the interaction of signal peptides ([@bib41]). The availability of this potent and stably bound inhibitor provided us with the opportunity to visualize the translocon trapped in the inhibited state.Figure 1The Structure of the Sec61 Translocon Inhibited by Mycolactone(A) The structure of mycolactone A/B (743 Da). The 12-membered lactone core is indicated, as are the two polyketide side chains, commonly referred to as the northern and southern chains. Mycolactone A/B is a 3:2 rapidly equilibrating mixture of *Z*-Δ4′,5′ and *E*-Δ4′,5′ geometric isomers at the second double bond in the southern fatty acid tail.(B) Mycolactone concentrations in purified ribosome-translocon complexes extracted from membranes treated (+) or not treated (−) with mycolactone, determined by high-resolution LC-MS with the extracted ion chromatogram peaks integrated to obtain the \[mycolactone+Na\]^+^ (m/z 765.4721--765.5103) ion eluting at 2.38--2.98 relative to the calibration curve.(C) Electron density for Sec61α in the presence of mycolactone. Electron density maps were low-pass-filtered to 5 Å; the density feature corresponding to mycolactone is colored pink. The insets show two close-up views centered on the mycolactone density.(D) The structure of the Sec translocon with Sec61α colored, with helices H1--H5 in blue, H6--H10 in red, Sec61β in green, and Sec61γ in orange. Mycolactone is shown as spheres, with carbon in white and oxygen in red.See also [Figures S1--S5](#mmc1){ref-type="supplementary-material"}.

Results {#sec2}
=======

Cryoelectron Microscopy of Mycolactone-Inhibited Ribosome-Translocon Complexes {#sec2.1}
------------------------------------------------------------------------------

Although there is, to date, no high-resolution crystal structure of a eukaryotic Sec61 homolog, cryoelectron microscopy of ribosome-translocon complexes has allowed visualization of translocons with different binding partners or captured in different states. We therefore purified ribosome-translocon complexes (RTCs) from canine microsomal membranes that had been incubated with mycolactone at a concentration that completely prevented prepro-α factor translocation ([Figure S1](#mmc1){ref-type="supplementary-material"}). Liquid chromatography-mass spectrometry (LC-MS) was used to confirm the presence of mycolactone in these complexes ([Figure 1](#fig1){ref-type="fig"}B; [Figure S2](#mmc1){ref-type="supplementary-material"}). In addition, to ensure that the observed changes were due to the presence of mycolactone rather than due to details of our preparation or imaging protocols, we prepared a control sample of ribosome-translocon complexes in the absence of inhibitor.

We next prepared grids to allow visualization of these samples by cryoelectron microscopy. Although samples prepared in standard holey grids or grids overlaid with a 2-nm layer of carbon showed preferred orientations, complexes vitrified on graphene oxide-coated grids allowed imaging of multiple views and generation of three-dimensional reconstructions ([Figures S3--S5](#mmc1){ref-type="supplementary-material"}; [Table 1](#tbl1){ref-type="table"}). Ribosomes were predominantly translocon bound, and particle subtraction and focused classification on mycolactone-bound translocons yielded a map with an overall resolution of 2.6 Å and local resolutions for Sec61α from 2.4--8.7 Å ([Figure 1](#fig1){ref-type="fig"}; [Figure S3](#mmc1){ref-type="supplementary-material"}). The resolution is highest for the C-terminal ribosome-bound half of Sec61α (H6--H10), whereas the N-terminal half (H1--H5) is more dynamic and less clearly defined ([Figure S3](#mmc1){ref-type="supplementary-material"}). A model was built containing all transmembrane helices of Sec61α, the majority of Sec61γ, and a poly-alanine helix for Sec61β. The control dataset generated an electron density map at an overall resolution of 2.8 Å in which the positions of the helices were essentially indistinguishable from the previously reported structure of a primed translocon ([@bib68]), indicating that the changes observed in the mycolactone-bound translocon were due to the presence of mycolactone ([Figures S5](#mmc1){ref-type="supplementary-material"}). An elongated density within the cytosolic side of the lateral gate of the translocon was the only difference between mycolactone-bound and mycolactone-free translocons that was not due to helix movement and was attributed to mycolactone ([Figure 1](#fig1){ref-type="fig"}C). A comparison of mycolactone-bound and mycolactone-free ribosome-translocon complexes revealed no differences in the conformation of the ribosome, the occupancy of tRNA-binding sites, or the presence of associated proteins because of the presence of mycolactone ([Figures S1](#mmc1){ref-type="supplementary-material"} and [S3--S5](#mmc1){ref-type="supplementary-material"}), supporting the finding that mycolactone does not directly affect translation elongation ([@bib20]).Table 1Refinement and Model Statistics-Ribosome:Sec61 + MycolactoneRibosome:Sec61**Data Collection and Processing**Magnification165,000165,000Voltage (kV)300300Electron exposure (e−/Å^2^)4949Defocus range (μm)−1.0 to −2.5−1.0 to −2.5Pixel size (Å)0.8220.822Symmetry imposedC1C1Initial particle images (no.)108,12949,733Final particle images (no.)45,73324,852Map resolution (Å)2.632.85Fourier Shell Correlation threshold0.1430.143**Refinement**Map pixel size (Å)1.033Map sharpening *B* factor (Å^2^)5.7Map lowpass filter (Å)4.0Model resolution (Å)4.0**Model Composition**Non-hydrogen atoms3,608Protein residues441LigandsMYC: 1**Average B Factors (Å2)**Protein65.98Ligands71.85**Root-Mean-Square Deviations (RMSDs)**Bond lengths (Å)0.006Bond angles (°)1.047**Validation**MolProbity score1.79Clashscore5.40Poor rotamers (%)0.53**Ramachandran Plot**Favored (%)91.61Allowed (%)8.39Disallowed (%)0.00

Mycolactone Stabilizes a Partially Activated Conformation of Sec61 {#sec2.2}
------------------------------------------------------------------

A comparison of the conformations of the mycolactone-bound and mycolactone-free translocons ([@bib68]) identified no differences in the ribosome-bound C-terminal half of Sec61α. However, in the presence of mycolactone, a major structural change was observed within the more flexible N-terminal half, with an ∼9-Å movement of the cytoplasmic ends of helices H2 and H3 and smaller tilting of helix H4. This movement of H2 and H3 away from H7 and H8 results in opening of the cytoplasmic side of the lateral gate ([Figure 2](#fig2){ref-type="fig"}). Toward the lumenal side of the translocon lies the plug helix. This plug is present in the primed conformation of the translocon ([@bib68]) but is displaced in the signal peptide-bound conformation, opening the channel ([@bib66]). In the presence of mycolactone, the plug helix is clearly visible in the electron density maps, retaining its α-helical character but showing a displacement of ∼7 Å from its location in the primed state. However, this displacement is not sufficient to allow channel opening, with the plug helix still occluding the channel ([Figure 2](#fig2){ref-type="fig"}).Figure 2The Mycolactone-Stabilized Conformation of the Sec TransloconStructural overlays of the mycolactone-bound conformation of Sec61α, with helices H1--H5 in blue and helices H6--H10 in red. This has been overlaid with the primed conformation (top panel; PDB: [3J7Q](pdb:3J7Q){#intref0165}), the open signal peptide-bound conformation (center; PDB: [3JC2](pdb:3JC2){#intref0170}), and the Sec62/63-bound conformation (bottom; PDB: [6ND1](pdb:6ND1){#intref0175}), all in white. The left panel shows the helices as cylinders. The center panel shows helices H2, H3, H7, and H8 in cartoon representation, with the lateral gate shown as a dotted line. The right panel shows a close up centered on the plug helix (P).

Comparison of the structure of the mycolactone-bound translocon with those of eukaryotic primed ([@bib68]), signal peptide-bound ([@bib66]), and Sec62/63-bound states ([@bib26]; [@bib71]; [Figure 2](#fig2){ref-type="fig"}) reveals mycolactone to stabilize a conformation of Sec61α most similar to that observed in the presence of a complex of Sec62 and Sec63. This conformation of Sec61α is associated with post-translational translocation, in which the translocon is poised to accept substrates and to be gated by inefficient signal peptides. Indeed, stabilization of this state by Sec62/63 is thought to facilitate translocation, making it surprising that this is the state stabilized by a translocation inhibitor.

A Proposed Binding Site for Mycolactone at the Cytoplasmic Entrance of the Channel {#sec2.3}
----------------------------------------------------------------------------------

Comparison of the electron density maps for mycolactone-bound and mycolactone-free translocons ([@bib68]) reveals a single density feature that was not attributed to helix movement ([Figure 1](#fig1){ref-type="fig"}C). Because mycolactone must be present in the translocon to account for stabilization of this conformation, we docked mycolactone into this density. This binding pocket lies between helices H2 and H8 of Sec61α, within a hydrophobic groove created by opening of the lumenal side of the lateral gate ([Figure 3](#fig3){ref-type="fig"}A). Residues that line this groove and contact mycolactone include hydrophobic side chains that form part of the pore ring (V85 and I179) and hydrophobic patch (L89 and I179) of Sec61α and are thought to play important roles in channel closure and signal peptide binding ([Figures 3](#fig3){ref-type="fig"}B and 3C). The electron density attributed to mycolactone consists of a wider central region into which we docked the lactone core of mycolactone. On either side of this are two narrower regions of density likely to correspond to the polyketide side chains. These are not sufficiently well defined to precisely place mycolactone because of the ∼5-Å resolution of this region of the map ([Figure S3](#mmc1){ref-type="supplementary-material"}) coupled with the potential for mycolactone isomerization ([@bib16]) and the inherent flexibility of its polyketide chains.Figure 3The Mycolactone Binding Site and the Location of Residues Whose Mutation Leads to Mycolactone Resistance(A) Structure of Sec61α, with helices H1--H5 in blue and H6--H10 in red. The electron density for mycolactone is shown as a white surface.(B) A close up of the mycolactone binding site, highlighting hydrophobic residues that lie in this pocket.(C) A second view of the mycolactone binding site from the cytoplasmic face, viewed approximately perpendicular to the membrane.(D) A view of the primed conformation of Sec61α, viewed from the same direction as in (C).(E and F) Two views of the outcome of molecular dynamics simulations in which mycolactone was allowed to move within a restrained translocon. The original position of mycolactone, determined by fitting into the electron density, is shown as orange sticks, whereas gray sticks show variation in the position of mycolactone through a 100-ns trajectory, and yellow sticks show the position of mycolactone at the end of the trajectory. The electron density for mycolactone is shown as a white surface.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

To further assess the pose of mycolactone within this binding site and to determine whether it remains stably bound during simulation, we used molecular dynamics ([Figures 3](#fig3){ref-type="fig"}E and 3F; [Figure S6](#mmc1){ref-type="supplementary-material"}). Two possible orientations of mycolactone could fit within the electron density, with the longer southern chain protruding into the hydrophobic environment of the lipid bilayer or into the core of the translocon. To assess the likelihood of each possible orientation, we modeled the *E*-Δ4′,5′ isomer of mycolactone, the presumptive active form ([@bib14]), into this density in either possible orientation, and molecular dynamics simulations were conducted to assess their stability. In both cases, mycolactone remained stably bound over the 100-ns time course of the simulation. However, the conformation in which the southern chain protrudes into the lipid bilayer showed less variation during the simulation and was better accommodated within the binding pocket as well as within the electron density, suggesting this to be the most likely binding mode. Here the lactone core forms the majority of the interaction with the translocon, with the northern chain also interacting, whereas the long southern chain is predominantly flexible and disordered.

Mycolactone Resistance Mutations Reduce Mycolactone Binding, Most Likely by Modulating Translocon Dynamics {#sec2.4}
----------------------------------------------------------------------------------------------------------

The structure of the mycolactone-bound translocon allowed us to revisit how Sec61α mutations cause resistance to inhibitors. A number of studies have identified mutations that overcome the cytotoxic effects of mycolactone. Indeed, the same mutations often affect multiple different inhibitors, supporting the idea of a common binding mode ([@bib2]; [@bib32]; [@bib40]; [@bib47]; [@bib48]; [@bib75]). We now conducted an additional forward genetic screen that identified nine substitutions in six codons that gave mycolactone resistance, five of which overlapped with those identified previously ([Figure 4](#fig4){ref-type="fig"}A; [Figure S7](#mmc1){ref-type="supplementary-material"}; [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}). Although not identified in our screen, mutation of T86 is also reported to confer resistance to mycolactone ([@bib75]). Unexpectedly, of the residues associated with resistance mutations, only T86 directly contacts mycolactone. Instead, the majority lie on or around the plug helix, on the lumenal side of the translocon, away from the mycolactone-binding pocket ([Figure 4](#fig4){ref-type="fig"}B). Indeed, no extra electron density is observed in the mycolactone-bound translocon, which directly contacts residues associated with resistance mutations.Figure 4The Location of Mycolactone Resistance Mutations and Their Effect on Mycolactone Binding(A) Parental HCT-116 cells and representative clones with different amino acid substitutions were tested for their sensitivity to mycolactone A/B. Data are expressed as a normalized viability index of cells treated with inhibitor for 5 days, after which metabolic activity was assessed with Resazurin dye (alamarBlue assay), and values were normalized to a DMSO control. The IC~50~ of wild-type cells for mycolactone A/B was 1.94 nM (1.44 ng/mL). Data are mean ± SEM of n = 3.(B) A representation of the Sec translocon with Sec61α colored, with helices H1--H5 in blue and H6--H10 in red, Sec61β in green, and Sec61γ in orange. Mycolactone is shown as spheres, with carbon in white and oxygen in red. Residues whose mutation leads to mycolactone resistance are represented as yellow spheres.(C and D) Microsomes were prepared from TRex-293 cells or those stably transfected with C-terminal FLAG-tagged mutant Sec61A1 constructs. Mycolactone-exposed RTCs were prepared, and the peak fractions were subjected to LC-MS.(C) Immunoblotting of peak fractions. Migration relative to known molecular weight markers is shown, as is optical density 260 (OD~260~). The location of an excised lane is indicated by a dotted line.(D) Relative mycolactone abundance in the RTCs was estimated using high-resolution LC-MS by integrating the extracted ion chromatogram peaks for the \[mycolactone+Na\]^+^ (m/z 765.4721--765.5103) ion eluting at 2.38--2.98 relative to a calibration curve. To compare between preparations, the data were standardized on ribosome concentration (calculated from OD~260~) or Sec61α abundance (pixel intensity of the immunoblot band). Triplicate analysis from n = 1.(E) Assessment of the dynamics of mycolactone bound to the translocon during 100-ns simulations for wild-type and mutant translocons. Helices H6--H10 were restrained, and movement was allowed for mycolactone and the remainder of the translocon. In each case, the root-mean-square deviation from the starting position is shown at each nanosecond for the southern chain, northern chain, and lactone core. Three independent simulations were conducted, and these plots show the average.See also [Figures S7--S9](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Although we cannot be sure why resistance mutations were not found in the binding pocket, this may be due to the essential role of residues that contact mycolactone. These include hydrophobic residues that play functionally important roles in the structure and dynamics of Sec61α, including roles in the pore ring (V85 and I179) and the hydrophobic patch (L89 and I179). It is therefore possible that mutations in these residues that cause sufficiently large changes in side-chain chemistry to reduce mycolactone binding also make the translocon non-functional, precluding their appearance in a forward genetic screen. Indeed, the naturally occurring mutation V85D, found in hypogammaglobulinemia, is defective in co-translational translocation ([@bib57]).

With the surprising finding that resistance mutations are not found in residues that contact mycolactone, we used LC-MS and molecular dynamics to assess whether these mutations affect binding of mycolactone to the translocon. To directly measure mycolactone binding, we prepared microsomes from unaltered TRex-293 cells as well as from cells stably overexpressing Sec61α with resistance mutations at positions S71, G80, and S82. RTCs were prepared in the presence of mycolactone, and LC-MS was used to quantify mycolactone in these complexes. In wild-type cells, we estimate that each translocon bound an average of 0.87 ± 0.04 mycolactone molecules. When performed with cells overexpressing mutant Sec61α variants, in each case, the average number of mycolactone molecules per translocon decreased, with reductions of 70%--80% when normalization was conducted using a Sec61α immunoblot ([Figures 4](#fig4){ref-type="fig"}C and 4D; [Figure S8](#mmc1){ref-type="supplementary-material"}). Because endogenous Sec61α remains in these preparations, this shows that all three mutations cause major reductions in the binding of mycolactone to the translocon.

In parallel, we performed molecular dynamics to assess the stability of mycolactone in the binding pocket. Long simulations of the entire ribosome-translocon system to observe Sec and mycolactone conformational dynamics were computationally prohibitive. However, short MD simulations can successfully be used to provide an assessment of binding stability ([@bib37]). Because helices H6--H10 of the translocon were equivalent in conformation between mycolactone-bound and -free conformations ([Figure 2](#fig2){ref-type="fig"}), we fixed these in position and allowed free movement of mycolactone and helices H1--H5. In three repeats of a 100-ns simulation, mycolactone remained stably bound. However, introduction of the S71F, G80W, and S82F mutations each reduced the stability of mycolactone binding, in particular of the northern chain ([Figure 4](#fig4){ref-type="fig"}E; [Figure S9](#mmc1){ref-type="supplementary-material"}). Together with MS analysis, these studies show that resistance mutations decrease mycolactone binding despite being in residues that do not make direct contact with mycolactone.

Therefore, the most probable hypothesis for how resistance mutations function is that they modulate translocon dynamics, reducing the likelihood of formation of the mycolactone binding pocket. To assess this, we measured the change in separation of three pairs of residues that contact mycolactone, V85-W379, L89-V382, and L89-W379, during the molecular dynamics simulations of mycolactone-bound S71F, G80W, and S82F described above ([Figure S9](#mmc1){ref-type="supplementary-material"}). Intriguingly, each mutation changed the separation of these residues in different ways. S82F seems to favor an opening of the lateral gate in the region of the mycolactone binding pocket, perhaps because of introduction of a bulky side chain in a site buried in the mycolactone-bound conformation. In contrast, G80W favored closing of the lateral gate. A conclusive analysis would require extensive simulations of complete RTCs and detailed biochemical analyses of the mutant translocons. However, our analysis suggests that favoring the open or closed state relative to the mycolactone-bound state can be associated with resistance. Indeed, a similar allosteric mechanism has been proposed to explain the role of the *prl* phenotypes that allow export of proteins with defective or absent signal peptides ([@bib31], [@bib32]; [@bib58]; [@bib62]). Most of the residues in which we identified resistance mutations are also associated with *prl* phenotypes ([Table S1](#mmc1){ref-type="supplementary-material"}), supporting the idea that their effects are the result of changes in translocon dynamics. Our findings therefore confirm that resistance mutations reduce mycolactone binding without being in residues that directly contact the inhibitor and suggest that this is achieved by changes in conformational dynamics that disfavor the mycolactone-bound conformation.

Discussion {#sec3}
==========

This study reveals the mode of action of Sec61α inhibitors while also highlighting unexpected features of the mechanism of the translocon. First we show that mycolactone wedges open the cytoplasmic side of the lateral gate of Sec61α. This stabilizes a conformation very similar to that stabilized by Sec62/63, which is poised and permissive for post-translational translocation. Therefore, unexpectedly, mycolactone does not stabilize the inactive translocon but traps the helices of Sec61α in a partly activated conformation.

The density attributed to mycolactone lies directly across the cytoplasmic side of the channel. Although the route the signal peptide takes during co-translational translocation is not fully resolved, the location of the engaged signal peptide has been mapped to a site within the lateral gate in translocating ribosome-translocon complexes ([@bib66]). The locations occupied by mycolactone and the signal peptide overlap and will be mutually exclusive in occupation. This suggests that the signal peptide reaches its binding site by passing through the region occupied by mycolactone and that the inhibitor directly prevents signal peptide-mediated opening of the channel and subsequent removal of the plug.

These findings also have consequences for our understanding of the dynamics of the translocon ([Figure 5](#fig5){ref-type="fig"}). The binding site for mycolactone will only be formed when the cytoplasmic side of the lateral gate opens through the tilting of helices H2 and H3 away from H7 and H8. It is hard to envisage mycolactone occupying this binding pocket when Sec61α is in the process of translocation because the translocating translocon will be open, and the nascent polypeptide chain is expected to occlude the mycolactone binding site. Indeed, this is supported by biochemical assays showing that mycolactone does not affect cross-linking of a substrate to Sec61α when added after translocation is initiated by microsome addition ([@bib41]). Instead, mycolactone will bind while the translocon is idle. This suggests that non-translocating Sec61α is in a dynamic equilibrium, transitioning between the closed state and a transient intermediate that resembles the inhibitor-bound state. This conformational mobility will be advantageous for the translocon because the plug helix remains in place, keeping the channel of the translocon closed to minimize ion leak, but movements in the lateral gate create an opportunity for signal peptide binding and gating. The finding that Sec62/63 stabilizes this intermediate to facilitate post-translational translocation supports this view. However, this intermediate is also susceptible to inhibition, with transient opening of the lateral gate creating the inhibitor binding pocket, allowing mycolactone to wedge open the lateral gate and block access to the signal peptide binding site.Figure 5A Model of the Mode of Action of MycolactoneIn this model, the ribosome-bound primed conformation of the Sec translocon is hypothesized to be in equilibrium with a second state (the putative intermediate), in which the lateral gate is open while the plug helix blocks the channel. This is similar in structure to the state stabilized by Sec62/63. Mycolactone can enter this intermediate state and stabilize its conformation while hindering access to the signal peptide binding site.

Translocation inhibitors with profoundly different chemical structures show cross-competition and are affected by the same resistance mutations ([@bib65]), suggesting that this mechanism is not restricted to mycolactone but common and widely exploitable. Indeed, our findings may also explain why the same resistance mutations affect the efficacy of inhibitors as diverse in structure as cyclic peptides, glycolipids, and polyketide lactones because they modulate formation of their shared binding site. Translocation inhibitors have been suggested as potential anti-cancer and anti-inflammatory agents ([@bib65]) and would be expected to have powerful activity against enveloped viruses. This structure not only yields new insight into the mechanism of the translocon but also provides invaluable insight to guide future rational drug design.

STAR★Methods {#sec4}
============

Key Resource Table {#sec4.1}
------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse monoclonal anti-Sec61αSanta Cruz BiotechnologyCat\#sc-393182, RRID: [AB_2301616](nif-antibody:AB_2301616){#intref0010}Rabbit polyclonal anti-Sec61βKelkar and Dobberstein, 2009N/ARabbit polyclonal anti-RS6Cell Signaling TechnologyCat\#2217, RRID: [AB_331355](nif-antibody:AB_331355){#intref0015}Mouse monoclonal anti-Ribophorin 2Santa Cruz BiotechnologyCat\#sc-166421 RRID: [AB_2238716](nif-antibody:AB_2238716){#intref0020}DYKDDDDK Tag Rabbit anti-Tag, PolyclonalInvitrogenCat\# PA1984B RRID: [AB_347227](nif-antibody:AB_347227){#intref0025}ECL Mouse IgG, HRP-linkedGE HealthcareCat\#NXA931 RRID: [AB_772209](nif-antibody:AB_772209){#intref0030}ECL Rabbit IgG, HRP-linkedGE HealthcareCat\#NA934 RRID: [AB_772206](nif-antibody:AB_772206){#intref0035}Goat Anti-Rabbit IgG (H+L) Antibody, Alexa Fluor 488 ConjugatedInvitrogenCat\# A-11008 RRID: [AB_143165](nif-antibody:AB_143165){#intref0040}**Chemicals, Peptides, and Recombinant Proteins**Mycolactone A/B[@bib59]CAS:222050-77-3L-\[S35\]-MethionineHartmann AnalyticCat\#SCM01DigitoninSigma-AldrichCat\#D141, CAS:11024-24-1Cotransin[@bib39]; [@bib40]CAS: 1000770-96-6Ipomoeassin F[@bib6]; [@bib75]CAS:915392-44-8Resazurin sodium saltSigma AldrichCat\#R7017, CAS:62758-13-8Mycolactone A/B, mixture of epimers at C12[@bib53], [@bib54]N/AParaformaldehydeSigma AldrichCat\#P6148**Deposited Data**Canine ribosome:Sec61 complex cryo-EM map in the presence of mycolactoneThis paperEMDB: 11064Canine Sec61 channel bound to mycolactone model coordinatesThis paperPDB: [6Z3T](pdb:6Z3T){#intref0045}Canine ribosome:Sec61 complex cryo-EM map in the absence of mycolactoneThis paperEMDB: 11064Original images and immunoblots, Sanger sequencing, viability assays and LC-MS dataThis paper<https://data.mendeley.com/datasets/cc92fyz9sv/1>**Experimental Models: Cell Lines**HCT-116 cell lineATCCCCL-247TRex-293 cell lineThermo FisherR71007TRex-293 Sec61α S71F C-terminal FlagThis paperN/ATRex-293 Sec61α G80W C-terminal FlagThis paperN/ATRex-293 Sec61α S82Y C-terminal FlagThis paperN/A**Oligonucleotides**Sec61A1_frag1F TAGCACTGACGTGTCTCTCGSigma AldrichN/ASec61A1_frag1R TCCCCATACATCCCGGTCATSigma AldrichN/ASec61A1_frag2F CTTCAACGGAGCCCAAAAGTSigma AldrichN/ASec61A1_frag2R GTGTTGTACTGGCCACGGTAGSigma AldrichN/ASec61A1_frag3F TCATCGCCACCATCTTTGTCTTSigma AldrichN/ASec61A1_frag3R GGACCATGGAGGTCTCTCGGSigma AldrichN/ASec61A1_frag4F TATACATAGTGTTCATGCTGGGCTSigma AldrichN/ASec61A1_frag4R ACACAGTGGAATGAAAGAATACGASigma AldrichN/ASec61A1_frag5F TAGTGTGCTGCCAGATTCCCSigma AldrichN/ASec61A1_frag5R TCAAATTCCATTCCTCGGCCASigma AldrichN/A**Recombinant DNA**pMXSec61S71FThermoFisher Scientific GeneArtN/ApMXSec61G80WThermoFisher Scientific GeneArtN/ApMXSec61S82YThermoFisher Scientific GeneArtN/ApNLF1-C (CMV/Hygro)PromegaCat\#N1361pNSec61S71FThis paperN/ApNSec61G80WThis paperN/ApNSec61S82YThis paperN/A**Software and Algorithms**CootEmsley and Cowtan, 2004<https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>Phenix[@bib1]<https://www.phenix-online.org/>UCSF Chimera[@bib50]<https://www.cgl.ucsf.edu/chimera/>UCSF ChimeraX[@bib18]<https://www.cgl.ucsf.edu/chimerax/>Relion 3.0[@bib74]<https://www3.mrc-lmb.cam.ac.uk/relion/index.php/Main_Page>UCSF MotionCor2[@bib73]<https://emcore.ucsf.edu/ucsf-motioncor2>CTFFIND 4.1[@bib52]<https://grigoriefflab.umassmed.edu/ctffind4>SIMPLE[@bib11]<https://simplecryoem.com>ResMap[@bib60]<http://resmap.sourceforge.net>EPU 2.3ThermoFisher ScientificN/AAdobe IllustratorAdobeN/AXcalibur 4.2 Quan BrowserThermo ScientificN/AChromas LiteTechnelysiumBLASTnNCBI<https://blast.ncbi.nlm.nih.gov/Blast.cgi>Prism 8.2.1GraphPadN/AExcel 2016MicrosoftN/APowerpoint 2016MicrosoftN/AImageJ 1.52pNIH<https://imagej.nih.gov/ij/>GROMACS 2019[@bib64]<http://www.gromacs.org/>VMD 1.9[@bib25]<https://www.ks.uiuc.edu/Research/vmd/>MDAnalysis[@bib43]<https://www.mdanalysis.org/>Python<https://www.python.org/>Matplotlib[https://doi.org/10.5281/zenodo.2577644](10.5281/zenodo.2577644){#intref0130}<https://matplotlib.org/>PyMOLThe PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC.<https://pymol.org/2/>**Other**Sephacryl S-300 HRGE HealthcareCat\#17059910Micrococcal nucleaseNew England BiolabsCat\#M0247SRabbit reticulocyte lysate, nuclease treatedPromegaCat\#L4960Albumin,bovine serum, protease freeThermoFisher ScientificCat\#11461655Graphene oxide dispersionGrapheneaCat\#947-768-1Quantifoil R 1.2/1.3 200 Mesh, copperQuantifoilCat\#Q2100CR1.34--20% TGX Mini-Protean precast gelsBioRadCat\#4561903Spectra broad-range protein markersThermo Fisher ScientificCat\#266234Simply BlueThermo Fisher ScientificCat\#10432072Immobilon-P PVDF membraneThermo Fisher ScientificCat\#15750319Immobilon Western chemiluminescent substrateSigma AldrichCat\# WBKLSMcCoy's 5A (modified) MediumThermoFisher ScientificCat\#11530646Foetal Bovine Serum, heat inactivated, SA originThermoFisher ScientificCat\#11550356Superscript IVLife TechnologiesCat\# 18090050GoTaq G2 Green MastermixPromegaCat\# M7822Dulbecco's Modified Eagle's Medium - high glucoseSigma AldrichCat\#D6429Fugene 6PromegaCat\#E2691Protease inhibitor cocktailSigma AldrichCat\#P8340

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Rachel Simmonds <rachel.simmonds@surrey.ac.uk>

### Materials Availability {#sec4.2.2}

All unique/stable reagents generated in this study (plasmids containing mutant human Sec61α and mycolactone-resistant cell lines) are available from the Lead Contact without restriction.

### Data and Code Availability {#sec4.2.3}

The electron microscopy datasets generated during this study, in the form of maps, are available at the electron microscopy data bank (EMD-11064). The model for the Sec translocon with mycolactone bound, generated during this study, is available at the protein data bank PDB: (6Z3T). Other data associated with the manuscript is available at <https://data.mendeley.com/datasets/cc92fyz9sv/1>.

Experimental Model and Subject Detail {#sec4.3}
-------------------------------------

### Cell lines {#sec4.3.1}

The male human colorectal cancer cell line HCT-116 (ATCC CCL-247) was maintained in McCoy's 5A (modified) medium supplemented with 10% fetal bovine serum (FBS) and 1x penicillin-streptomycin (both Thermo Fisher Scientific). TRex-293 cells, derived from the female human embryonic kidney line HEK293, were maintained in high glucose DMEM, supplemented with 10% FBS. Cells were routinely cultured at 37°C and 5% CO2. We do not routinely authenticate our cell lines.

Method Details {#sec4.4}
--------------

### Mycolactone {#sec4.4.1}

We used synthetic mycolactone A/B, kindly provided by Prof Yoshito Kishi (Harvard University) ([@bib59]) for all of the experiments described in this manuscript. Mycolactone A/B is a 3:2 rapidly equilibrating mixture of *Z*-Δ^4',5′^ (A) and *E*-Δ^4',5′^ (B) geometric isomers at the second double bond in the southern fatty acid tail. Since the two isomers cannot be separated in light, as they rapidly re-equilibrate to the 3:2 ratio, we refer to them as mycolactone. Mycolactone was provided in ethyl-acetate, dried down under nitrogen and resuspended in DMSO at 0.5 mg/ml. Aliquots are protected from light and stored at −80°C.

For selection of stably transfected TRex-293 cells to derive overexpressing mycolactone resistance mutations, we used synthetic mycolactone A/B as a mixture of epimers at C12′, kindly provided by Dr Nicolas Blanchard ([@bib53], [@bib54]) (French National Centre for Scientific Research), which is available in the greater amounts needed for cells under selection. However, tests performed with stable clones used mycolactone A/B ([@bib59]).

### Purification of ribosome-translocon complexes {#sec4.4.2}

Ribosome-associated Sec61 complexes, known as ribosome-translocon complexes or RTCs, were prepared largely as described ([@bib68]). Briefly, rough microsomal membranes (CPMM) were prepared from dog pancreas as described ([@bib69]) and stored at −80°C in 50 mM triethanolamine (pH 7.5), 250 mM sucrose, 1 mM DTT. Aliquots were incubated with 1 mM CaCl~2~ and 150 U/ml micrococcal nuclease for 7 min at room temperature. The reaction was stopped by addition of 2 mM EGTA and microsomes were flash-frozen in 50 μl aliquots. Mycolactone (1 μg/ml) was prepared by dilution in 0.1% (w/v) BSA from a concentrated stock. Control samples contained 0.1% (v/v) DMSO in BSA. Microsomes were thawed on ice and mycolactone was added to 200 ng/ml (269.2 nM). After gentle mixing, samples were incubated on ice for 30 min. Microsomes were solubilised by incubation for 10 min on ice with an equal volume of 100 mM HEPES pH 7.5, 800 mM KOAc, 20 mM MgOAc, 3.5% (w/v) digitonin, 2 mM DTT. Samples were centrifuged at 20,000 x g for 15min at 4°C. An aliquot of supernatant (5μl) was removed for LC-MS analysis and the rest was applied to a 1 mL Sephacryl-300 column pre-equilibrated with ice cold column buffer (50mM HEPES pH7.5, 200 mM KOAc, 10mM MgOAc, 0.25% (w/v) digitonin, 1 mM DTT). Samples were eluted at 4°C in column buffer and collected in approximately 100 μl fractions. Absorbance at 260 nm was estimated using a Nanodrop (Thermo Fisher) and the initial peak eluting fractions were pooled. Samples were re-centrifuged at 20,000 x g for 15 min at 4°C and processed immediately for electron cryo-microscopy.

### *In vitro* translation/translocation assays {#sec4.4.3}

*In vitro* translation/translocation assays were performed as previously described ([@bib20]). Briefly, mycolactone was added to micronuclease-treated canine pancreatic microsomes and incubated on ice for 20 min in the dark. *In vitro* translation reactions were carried out in a 25 μl volume using nuclease-free rabbit reticulocyte lysates (Promega) according to manufacturer's instructions, with 0.5 μg prepro-α Factor mRNA and 35-S methionine. Microsomal membranes, when present, made up 10% of the final volume of the reaction mix. Samples were incubated for 30 min at 30°C and the reaction was stopped with the addition of an equal volume of 2x Laemmli sample buffer. Proteins were separated by SDS-PAGE on 4%--15% acrylamide gels, fixed, stained, and dried, then visualized with a Typhoon Phosphorimager (GE Healthcare).

### Liquid chromatography mass spectrometry {#sec4.4.4}

Liquid chromatography mass spectrometry (LC-MS) was performed on a Thermo Scientific Ultimate3000 UHPLC system equipped with a binary solvent manager, column manager, and autosampler, coupled to a Thermo Orbitrap Q-Exactive Plus mass spectrometer operating with the standard electrospray ionization interface and the following conditions: spray voltage 4 kV, capillary temp. 375°C, sheath gas 60 psi, aux gas 20 psi, S lens RF level 100%, resolution 70,000, divert valve schedule (to divert sample buffer components away from MS): 0-2.3 min, waste; 2.3-3.0 min, MS; 3.0-5.0 min, waste. Liquid chromatography conditions were as follows: injection volume 10 μL; column: Phenomenex Luna Omega (C18 porous silica, 2.1 × 50 mm, 5 μm particle size, 100 Å pore size); column temp. 25°C, flow rate 0.5 mL min^-1^; mobile phase Solvent A: aqueous ammonium acetate (10mM), pH 6.9; Solvent B: acetonitrile; gradient 0-1 min, 5% B; 1-2 min, 5%--90% B; 2-3.5 min, 90% B; 3.5-4.5 min,90%--5% B; 4.5-5 min, 5% B; autosampler temp. 10°C.

The identity and LC-MS retention time of pure mycolactone A/B bound to microsomes was confirmed by both accurate mass and MS/MS of the \[M+Na\]^+^ ion which showed the same fragmentation pattern of sodium adducts reported previously ([@bib23]) (core + northern chain *m/z* 429; southern fatty acid *m/z* 359).

For mycolactone quantification, a set of standards for an LC-MS calibration curve were set up using synthetic mycolactone A/B dissolved into acetonitrile/water (1:1). The standards were analyzed by LC-MS once before each repeat of experimental samples. Extracted ion chromatograms (EIC) for mass range 765.4721 -- 765.5103 (mycolactone A/B \[M+Na\]^+^) were produced using Thermo Scientific Xcalibur 4.2 Quan Browser. Peak areas were first generated automatically for retention time range 2.68 min with window 36 s (2.38 -- 2.98 min), ICIS peak integration using smoothing points 7, baseline window 40, area noise factor 5, peak noise factor 10. This was followed by manual adjustment of the integration to include the entire EIC peak.

Experimental samples were: freshly prepared stocks of mycolactone (13.46 μM; 10 μg/ml) in 0.1% (w/v) BSA diluted 1:50 or 1:500 in acetonitrile/water (1:1), total extract from microsomes incubated with or without mycolactone diluted 1:10 in acetonitrile/water (1:1), and pooled Sephacryl-300 peak fractions containing RTCs (undiluted). Each sample was run three times with blank runs in between. Mycolactone concentrations were determined relative to the calibration curve.

### SDS-PAGE and immunoblotting {#sec4.4.5}

Aliquots of column eluted fractions were separated by SDS-PAGE on 4%--20% acrylamide gradient gels (Bio-Rad) alongside Spectra broad-range protein markers (Thermo Fisher Scientific). Proteins were stained with Simply Blue (Thermo Fisher Scientific) or blotted onto PVDF membranes. After transfer, blots were fixed with 5% acetic acid and blocked with 5% milk. Primary antibodies used were: mouse monoclonal anti-Sec61α; rabbit polyclonal anti-Sec61β (Kind gift from the Dobberstein lab) ([@bib34]); rabbit polyclonal anti-ribosomal protein S6 and mouse monoclonal anti-ribophorin 2 (Santa Cruz Biotechnology, sc-166421). Secondary antibodies were ECL Mouse IgG, HRP-linked (GE Healthcare, NXA931) and ECL Rabbit IgG, HRP-linked (GE Healthcare, NA934). Western blots were incubated with Immobilion Chemiluminescent HRP substrate and imaged using a Vilber Fusion FX imaging system. Images presented here were inverted using ImageJ v.1.52p.

### Grid preparation and data acquisition {#sec4.4.6}

Carbon-coated holey grids (Quantifoil, R1.2/1.3, 200 mesh) were used for the preparation of graphene-oxide grids. The grids were plasma-cleaned using a Quorum device at 50 mA for 60 s. For each grid, 3 μL of 0.2 mg/ml graphene oxide dispersion (Graphenea) was applied on the carbon surface, manually blotted, and allowed to dry overnight.

A 4 μL sample with an absorbance of 10 at 260nm was applied on the surface of each grid and vitrified by plunge-freezing in liquid ethane using a Vitrobot (FEI) with an incubation time of 15 s, a blotting time of 5 s and a blotting force of −15 at 4°C.

Data were collected manually using the acquisition software EPU on a Titan Krios transmission electron microscope (FEI) at a defocus range between 1 and 2.5 μm. All data were recorded on a K2 detector under low dose conditions with a nominal pixel size of 0.822 Å/pixel on the object scale. A total of 5062 and 3833 micrographs were collected for RTCs with and without mycolactone, respectively. Each micrograph experienced a total exposure of ∼49 electrons per Å^2^ fractionated into 32 frames. Foil holes containing the thinnest regions of ice and darkest edges were manually selected as they mostly contained single layer graphene oxide and showed higher signal-to-noise ratio.

### Image processing {#sec4.4.7}

Original movie frames were motion corrected and combined using MotionCor2 ([@bib73]). The contrast transfer function parameters were estimated via CTFFIND4.1 ([@bib52]). All micrographs were screened manually for graphene oxide and ice quality. Particles were picked automatically with SIMPLE ([@bib11]). All classifications and refinements were performed using Relion3 ([@bib55]; [@bib74]). After reference-free 2D classification, particles (76,650 for RTCs with mycolactone, 35,366 for the control dataset) were subjected to an extensive 3D classification into 10 classes after an initial round of refinement.

The main differences between the three-dimensional classes was the absence or presence of eEF2, while most ribosomes contained tRNA in P/E-state or E-state. Two main classes were selected, which included ribosomes with eEF2 (32,456 particles in the presence of mycolactone, 8,607 in the control dataset) and without eEF2 (18,365 particles with mycolactone, 16,245 without). Comparison of these ribosome states with those seen by [@bib68], who used a similar protocol for purification of ribosome-translocon complexes, revealed similarities and differences. Voorhees observed 13% active ribosomes (with A/P and P/E-site tRNAs), 65% without tRNA but with eEF2 and 22% empty ([@bib68]). The [@bib68] data share with our findings the presence of a majority of idle ribosomes and the surprising presence of a large fraction containing elongation factor eEF2. The major difference in ribosome conformation when compared with Voorhees is the presence of E or P/E site tRNAs in our RTCs, while [@bib68] observed predominantly tRNA-free ribosomes. We are not sure of the reasons for the differences here, but they might be due to different sources of microsomes (porcine versus canine) or subtle differences in the preparation procedure or time taken for purification.

For each state, 60S-Sec61 masked refinement, followed by particle subtraction of the ribosome core, were carried out. The subtracted particles were used for focused 3D classification with a mask applied around Sec61. The best classes were selected and subjected to 60S-Sec61 masked 3D refinement after particle polishing and CTF refinement. Particles from the two reconstructions obtained were combined, as no differences were observed in the conformation of the translocon, followed by a final 60S-Sec61 masked refinement. In the case of the control dataset, the same pipeline was used, without focused classification. All final reconstructions were subjected to post processing using a wide soft edge mask. This resulted in final resolutions of 2.63Å and 2.85Å, according to the FSC 0.143 criterion following the Relion gold-standard refinement ([@bib56]). Local resolution at the translocon was estimated using ResMap ([@bib60]). For better visualization and interpretation of the Sec density, and due to the heterogenous resolution across the translocon, the map used for model building was lowpass-filtered to 4Å.

### Homology modeling and refinement of atomic models {#sec4.4.8}

The structure of Sec61 was built using the structures of the primed state (RCSB code 3J7Q) and that of the signal peptide-engaged state (RCSB code 3JC2) as reference models. The model was built in COOT ([@bib12]) and refined using Phenix ([@bib1]) using Ramachandran and secondary structure restraints.

### Molecular dynamics simulations {#sec4.4.9}

The final model derived from electron cryo-microscopy was used as the starting point for molecular dynamics simulations. The original conformation had mycolactone docked with the southern chain projecting toward the lipid phase while in the reversed conformation, the southern chain projected toward the translocon. The presumptive active form, the *E*-Δ^4\'5^\' isomer, was selected for the simulations. The parameters for mycolactone were taken from ([@bib38]), who developed them using the General Amber force field (GAFF) ([@bib70]) in combination with the restrained electrostatic potential (RESP) approach ([@bib3]) employed for optimization of partial charges. The Amber 99SB-ILDN force field ([@bib36]) was adopted for Sec61 in conjunction with the TIP3P water model ([@bib30]). The POPC lipids were represented with the Slipids force field ([@bib27], [@bib28], [@bib29]).

The Sec61/mycolactone complex was first oriented with the translocon pore axis aligned coincident with the membrane normal of a pre-equilibrated POPC lipid bilayer containing 512 lipids, ensuring that the transmembrane helices of the Sec61α overlap with the hydrophobic region of the lipid membrane. Heavy atoms were position-restrained with a harmonic potential and a strong force constant of 10^5^ kJ mol^-1^ nm^-2^ and the inflateGRO tool ([@bib33]) was executed to rescale the lipid atom coordinates by a factor of four. A series of 25 iterations of shrinking and energy minimizing was performed until the POPC area per lipid was 71 Å^2^, a little above the equilibrium area per lipid of 65.8 Å^2^ ([@bib61]). The system was subsequently solvated and any water molecules inserted in the lipid phase were deleted. NaCl was added to neutralize the system and to provide a physiological ion concentration of 0.15 M.

Molecular dynamics simulations were performed using the GROMACS software package, version 2019 ([@bib64]). Initially, the system was energy minimized with the steepest descent algorithm until the maximum force did not exceed 100 kJ mol^-1^ nm^-1^. A short equilibration run in the NVT ensemble was carried out for 5 ns and the temperature was stabilized at 310 K with the velocity-rescale thermostat ([@bib5]) and a coupling constant of 0.1 ps. An additional equilibration step was performed subsequently in the NPT ensemble for 10 ns. In this case, the temperature was maintained at 310 K using the Nosé--Hoover thermostat ([@bib24]; [@bib44], [@bib45]) and a time constant of 0.5 ps, while the target pressure of 1 bar was reached using the Parrinello-Rahman barostat ([@bib46]; [@bib49]) and a semi-isotropic coupling with a time constant of 5 ps. For the MD production runs, the protein backbone atoms were position-restrained by applying a soft harmonic potential with a force constant of 500 kJ mol^-1^ nm^-2^, in order to ensure that the Sec61 state obtained from electron microscopy would be maintained despite the absence of the ribosome during simulations. Periodic boundary conditions were applied in all three dimensions. The hydrogen-containing bonds were constrained using the LINCS algorithm ([@bib22]). Neighbor searching, Lennard-Jones interactions and real-space Coulomb interactions were cut off at 10 Å. A dispersion correction was applied to energy and pressure to account for truncation of Lennard-Jones interactions. The particle-mesh Ewald summation was adopted for treatment of reciprocal-space electrostatic interactions with a cubic interpolation and a grid spacing of 1.2 Å. The time step was 2 fs and the leap-frog algorithm was selected for integration of the equations of motion. Coordinates were saved every 10 ps. Three repeats of 100 ns-long MD runs were subsequently performed for each system, amounting to a total simulation time of 600 ns.

To investigate the effect of mutations on mycolactone stability, three mutant systems were generated (S71F, G80W and S82F) using the mutagenesis tool of PyMOL (The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC.). The starting configuration was again the model derived from electron cryo-microscopy, with mycolactone docked in the original conformation. For system setup, equilibration and production runs, the same parameters and procedure as described above were adopted, with the exception that for production runs, position restraints were applied only to the heavy atoms of the Sec61γ subunit and the transmembrane helices H6-H10 of Sec61α to allow the rest of Sec61α to adapt to conformational changes caused by the presence of the mutation. For each mutant system and the WT, three 100 ns-long production runs were performed, resulting in a total simulation time of 1.2 μs.

The VMD software ([@bib25]) was used for visualization and the MDAnalysis package ([@bib43]) for trajectory analysis.

### Forward genetic screen and viability assays {#sec4.4.10}

The forward genetic screen in DNA damage repair-resistant HCT-116 cells was performed as described ([@bib32]; [@bib47]). The mutagen was ethyl methane sulphonate and selection was with 10 ng/ml (13.5 nM) mycolactone A/B. The cDNA for SEC61A1 was sequenced in resistant clones by RT-PCR. Total RNA (1 μg) was reverse transcribed using Superscript IV reverse transcriptase (Life Technologies) according to the manufacturer's instructions. The coding regions of SEC61A1 were amplified in four overlapping fragments using primers Sec61A1_frag1F/ Sec61A1_frag1R, Sec61A1_frag2F/ Sec61A1_frag2R, Sec61A1_frag3F/ Sec61A1_frag3R, Sec61A1_frag4F/ Sec61A1_frag4R with GoTaq G2 Green Mastermix (Promega). In some cases, confirmation of mutations used an additional fifth fragment using primers Sec61A1_frag5F/ Sec61A1_frag5R. The cycling conditions were 95ᵒC for 2 min, 35x cycles of 95ᵒC for 30 s, 58ᵒC for 30 s and 72ᵒC for 1 min, then 5 min at 72ᵒC. After clean-up, 70ng of each PCR product along with the corresponding forward primer were sent for Sanger sequencing using the Eurofins Mix2Seq service. Returned sequences, covering the entire coding region were analyzed using Chromas and BLASTn to identify the mutations. No homozygous mutations were identified. The parental cells and all resistant cell lines were heterozygous for a silent C/T transition in Thr445 (ACC/ACT). Almost all clones analyzed showed heterozygous mutations of single alleles. One exception was Hct7 which showed both Q127K and S82Y. Hct30 carried R66K and potentially P140T (as yet unconfirmed).

For viability assays, cells were seeded at 1000 cells/well and then treated with mycolactone, cotransin ([@bib40]) (CT8: kind gift of Jack Taunton), or ipomoeassin F ([@bib6]) (kind gift of Wei Shi) for 5 days. Then resazurin was added to a final concentration of 0.01 mg/ml. After 4 h further incubation, viability was measured as emission at 620 nm at excitation 580 nm using a BMG Fluostar Optima Microplate Reader. Data are expressed as a viability index, representing the relative signal compared to the negative control (DMSO-treated cells).

### Generation of mycolactone resistant cell lines {#sec4.4.11}

Synthetic C-terminal Flag-tagged Sec61A1 genes containing the mutations S71F, G80W and S85Y were generated (Thermo Fisher GeneArt) and cloned into the pNLF1-C vector (Promega), replacing the nanoluciferase insert. The plasmid was digested with *MluI* and 2 μg transfected into TRex-293 cells (Thermo Fisher) with Fugene (Promega) according to the manufacturer's instructions. Cells were selected for one week in the presence of 10 ng/ml (13.5 nM) mycolactone epimers (kind gift from Dr Nicolas Blanchard, CRNS France) ([@bib53], [@bib54]) and then for 1 week with 600 μg/ml hygromycin (Thermo Fisher). Expression of the mutant gene was confirmed by immunoblotting, and/or immunofluorescence, for the Flag tag. Single clones were selected for analysis.

### Immunofluorescence {#sec4.4.12}

Cells were transiently transfected with plasmids containing mutant Sec61 genes, incubated overnight, then seeded onto coverslips. After a further 24 hr incubation, cells were fixed with 4% paraformaldehyde in PBS and blocked with 1% BSA/PBS. Coverslips were incubated with anti-Flag antibody followed by Alex488 conjugated anti-rabbit antibody, then counterstained with DAPI.

### Microsome preparation {#sec4.4.13}

Crude rough microsomes were prepared from cells by the method described in [@bib7] with minor variations. Briefly, wild-type TRex-293 cells and those clones overexpressing Sec61α mutants were grown to 70%--90% confluency on eight 500 cm^2^ plates, collected in ice-cold PBS using cell lifters (Costar), centrifuged at 500 x g for 5 min at 4°C, and washed twice in ice-cold PBS. The cell pellet was resuspended in 3 pellet volumes of ice-cold buffer (10 mM HEPES, pH 7.4, 250 mM sucrose, 2 mM MgOAc). Cells were lysed in the cold (4°C) by 25 passes through a 25-gauge needle using a 10 mL syringe. The lysates were centrifuged at 3,800 x g for 30 min at 4°C. The supernatant was centrifuged at 75,000 x g for 1 h at 4°C in an SW55Ti rotor (Beckman Coulter). The membrane pellet was resuspended in microsome buffer (10 mM HEPES, pH 7.4, 250 mM sucrose, 1 mM DTT). Aliquots were taken at each stage for analysis by immunoblotting and assessment of absorbance at 260 nm. RTCs were isolated from cell derived microsomal preparations as described above for CPMM.

### Figure preparation {#sec4.4.14}

Figures were prepared using the programs Chimera ([@bib17]), ChimeraX ([@bib18]) and GraphPad Prism versions 7.0 or 8.2.1 (GraphPad Software).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

For mycolactone quantification by LC-MS, the calibration curve was established using the mean of the three repeat runs and the slope and intercept were calculated (Microsoft Excel 2016) for interpolation of mycolactone concentrations in samples. In order to compare TRex-293 cells to those overexpressing Sec61α mutants, the absorbance at 260 nm was used to estimate the concentration of RTCs in the recovered samples, using a μM extinction coefficient of 60.8 ([@bib8]), for the 80S ribosome. The ratio of mycolactone:RTCs was normalized to wild-type cells. Alternatively, the pixel intensity of the Sec61α band from immunoblots of equal volumes of recovered RTCs (measured using ImageJ v.1.52p) was used to estimate the normalized relative ratio. Here, the individual data from the triplicate measurements from a single run is shown. Since the endogenous Sec61α was not depleted from the cells prior to the analysis, all preparations contain some wild-type Sec61α.

For quantification of cell viability, each biological repeat was performed in triplicate. The data were normalized to the mean of the absorbance at 620 nm for DMSO-treated cells (solvent control). When combining the data from independent biological repeats, the mean of each normalized technical triplicate was taken. The IC~50~ for wild-type cells was calculated using log(inhibitor) versus response -- variable slope (four parameter) using Graphpad v. 8.2.1. No slopes were fitted to the resistant clones, as the fit was ambiguous, and no statistical comparison was performed. In the figure legends, n is the number of biological repeats (independent experiments).
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